Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE

References

• Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti‐Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594–602
   PubMed Web of Science ®Google Scholar
• St Clair E. W., van der Heijde D. M., Smolen J. S., Maini R. N., Bathon J. M., Emery P., , Active‐Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432–43
   PubMed Web of Science ®Google Scholar
• Pincus T. Limitations of randomized controlled clinical trials to depict accurately long‐term outcomes in rheumatoid arthritis. Z Rheumatol 1998; 57: 46–9
   PubMedGoogle Scholar
• Van Vollenhoven R. F., Brannemark S., Klareskog L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression‐like effect. Ann Rheum Dis 2004; 63: 426–30
   PubMed Web of Science ®Google Scholar
• Van der Heijde D. M. F. M., van ’t Hof M. A., van Riel P. L. C. M., van de Putte L. B. A. Development of a disease activity score based on judgement in clinical practice by rheumatologists. J Rheumatol 1993; 20: 579–81
   PubMed Web of Science ®Google Scholar
• Prevoo M. L. L., van ’t Hof M. A., Kuper H. H., van Leeuwen M. A., van de Putte L. B., van Riel P. L. Modified disease activity scores that include twenty‐eight‐joint counts. Arthritis Rheum 1995; 38: 44–8
   PubMed Web of Science ®Google Scholar
• Viney R., Savage E., Louviere J. Empirical investigation of experimental design properties of discrete choice experiments in health care. Health Econ 2005; 14: 349–62
   PubMed Web of Science ®Google Scholar
• van Vollenhoven R. F., Klareskog L. Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry. Arthritis Rheum 2003; 48: 1500–3
   PubMed Web of Science ®Google Scholar
• Feltelius N., Fored C. M., Blomqvist P., Bertilsson L., Geborek P., Jacobsson L. T., , ARTIS Group, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005; 64: 246–52
   PubMed Web of Science ®Google Scholar
• Berger A., Edelsberg J., Li T. T., Maclean J. R., Oster G. Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother 2005; 39: 2021–5
   PubMed Web of Science ®Google Scholar
• Finckh A., Simard J. F., Gabay C., Guerne P‐A., SCQM physicians. Evidence for differential acquired drug resistance to anti‐tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 746–52
   PubMed Web of Science ®Google Scholar
• Vander Cruyssen B., Van Looy S., Wyns B., Westhovens R., Durez P., Van den Bosch F., et al. Four‐year follow‐up of infliximab therapy in rheumatoid arthritis patients with long‐standing refractory disease: attrition and long‐term evolution of disease activity. Arthritis Res Ther 2006; 8: R112
   PubMed Web of Science ®Google Scholar
• Coletta A. P., Clark A. L., Banarjee P., Cleland J. G. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail 2002; 4: 559–61
   PubMed Web of Science ®Google Scholar
• Maini R., St Clair E. W., Breedveld F. C., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti‐tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932–9
   PubMed Web of Science ®Google Scholar
• Westhovens R., Yocum D., Han J., Berman A., Strusberg I., Geusens P., et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo‐controlled trial. Arthritis Rheum 2006; 54: 1075–86
   PubMed Web of Science ®Google Scholar
• St Clair E. W., Wagner C. L., Fasanmade A. A., Wang B., Schaible T., Kavanaugh A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trial. Arthritis Rheum 2002; 46: 1451–9
   PubMed Web of Science ®Google Scholar
• Pendley C., Schantz A., Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 2003; 5: 172–9
   PubMedGoogle Scholar